Denise Kazzaz

Denise Kazzaz supports manufacturers in evidence-based insights to inform clinical and economic value propositions and evidence strategies.

With several years of experience in oncology, she has extensive knowledge of biosimilars, oral dispensing market uptake, value frameworks, site of care assessments, and integrated care delivery models. Denise is part of the Market Access team at Avalere but also works with various cross-functional teams dedicated to value assessments and frameworks.

Prior to joining Avalere, Denise was director of Scientific Client Strategies and Real-World Evidence at Xcenda, serving clients in retrospective real-world studies as well as qualitative and quantitative primary research efforts. Before Xcenda, Denise worked in a variety of leadership roles in Healthcare Informatics and Market Analytics at US Oncology/McKesson Specialty Health.

Denise holds a BA in psychology and statistics from Carnegie Mellon University.

Authored Content

ICER is eager to position itself as the primary comparative and cost-effectiveness research body in the US. While their activity has been traditionally more limited to product-specific reviews, the Institute is increasingly looking to shape the broader debate around value and drug pricing.